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Abstract
Background: Canine parvovirus 2 (CPV-2) remains a significant worldwide canine pathogen and the most common
cause of viral enteritis in dogs. The 1 L15 and 7 L15 peptides overlap each other with QPDGGQPAV residues (7-15
of VP2 capsid protein of CPV) is shown to produce high immune response. PLGA nanoparticles were demonstrated
to have special properties such as; controlled antigen release, protection from degradation, elimination of booster-
dose and enhancing the cellular uptake by antigen presenting cells. Nevertheless, there is no study available in
literature, about developing vaccine based on PLGA nanoparticles with adjuvant properties against CPV.
Thus, the aim of the present study was to synthesize and characterize high immunogenic W-1 L19 peptide (from
the VP2 capsid protein of CPV) loaded PLGA nanoparticle and to evaluate their in vitro immunogenic activity.
Results: PLGA nanoparticles were produced with 5.26 ± 0.05 % loading capacity and high encapsulation efficiency
with 81.2 ± 3.1 %. Additionally, it was evaluated that free NPs and W-1 L19 peptide encapsulated PLGA
nanoparticles have Z-ave of 183.9 ± 12.1 nm, 221.7 ± 15.8 nm and polydispersity index of 0.107 ± 0.08, 0.135 ± 0.12
respectively. It was determined that peptide loaded PLGA nanoparticles were successfully phagocytized by
macrophage cells and increased NO production at 2-folds (*P < 0.05) in contrast to free peptide, and 3-folds
(*P < 0.01) in contrast to control.
Conclusion: In conclusion, for the first time, W-1 L19 peptide loaded PLGA nanoparticles were successfully
synthesized and immunogenic properties evaluated. Obtained results showed that PLGA nanoparticles enhanced
the capacity of W-1 L19 peptide to induce nitric oxide production in vitro due to its adjuvant properties. Depend
on the obtained results, these nanoparticles can be accepted as potential vaccine candidate against Canine
Parvovirus. Studies targeting PLGA nanoparticles based delivery system must be maintained in near future in order
to develop new and more effective nano-vaccine formulations.
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Background
Canine parvovirus (CPV) is a small, non-enveloped, au-
tonomously replicating Single-strained DNA virus [1], re-
mains a significant worldwide canine pathogen [2], is the
cause enteric and myocardial disease in dogs [3, 4]. In ex-
perimentally affected dogs, mortality without treatment
has been reported as high as 91 % [2, 5]. The two peptides
overlap each other with the sequence QPDGGQPAV resi-
dues (7 to 15 of VP2) 1 L15 (MSDGAVQPDGGQPAV)
and 7 L15 (QPDGGQPAVRNERAT), have different po-
tencies in inducing virus-neutralizing antibodies, produce
good immune response in mice and immunogenic in sev-
eral animal species [6, 7]. Therefore, different approaches,
particularly using these peptide sequences, are available
for developing synthetic peptide based vaccines against
Canine Parvovirus [6–9]. However, synthetic peptides
when used as a vaccine, without a delivery system have
been shown to be ineffective due to its rapid degradation
by proteases, along with its poor cellular uptake and im-
munogenicity [10]. In order to elicit a higher immune re-
sponse and improve the efficiency of peptide-based* Correspondence: serapacar5@gmail.comChemical and Metallurgy Faculty, Bioengineering Department, Yildiz
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vaccine, it is generally necessary to use a carrier system
such as protein, polymer or nano-micro particles.
Nanoparticle based antigen delivery system is a rapidly
developing area within nanotechnology. Especially nano
sized particular system based on biodegradable polymers
offer potential solution to disadvantages of the current
vaccines [11]. Poly(DL,lactic-co-glycolic acid) (PLGA) is
approved by Food and Drug Administration (FDA) and
widely used copolymer for nanoparticular delivery sys-
tem, owing to its biodegradability and biocompatibility
[12]. Encapsulation of vaccine antigens using PLGA
nanoparticles provides several advantage over the other
antigen delivery systems, such as; (i) antigen can be con-
trolled released over a longer period [13], (ii) antigen
can be protected against degradation in the presence of
proteolytic enzymes [14], (iii) eliminated the need for
booster dosed [15], (iv) enhance the antigen cellular up-
take by antigen presenting cells (APC) [13, 14]. More-
over, their submicron size and their large specific surface
area favor their adsorption compared to larger carriers
[16]. According to these significant properties of PLGA
polymer were studied in order to develop new peptide
based vaccine delivery systems against infectious disease
such as Bacillus anthracis [11], Hepatitis B [17, 18],
Chlamiydia Trachomatis [19], and also against allergic
asthma [20], melanoma cancer [21]. However, to our
knowledge, there is no study available in literature, in
regards to develop vaccines based on PLGA nanoparti-
cles with adjuvant properties against CPV.
The main goal of the present study was to synthesize
and characterize PLGA nanoparticle loaded with high
immunogenic W-1 L19 peptide sequences from the VP2
capsid protein of CPV and to evaluate their in vitro
immunogenic activity. For this purpose, loading capacity,
encapsulation efficiency, antigen release and morpho-
logical investigation of the nanoparticles were conducted.
Additionally, in vitro cytotoxicity of nanoparticles was in-
vestigated on J-774 cell lines and finally potency of PLGA
nanoparticles to induce NO production at non-toxic con-
centrations were evaluated in macrophages.
Methods
Materials
The water-soluble synthetic peptide representing W-
1 L19 from the VP2 capsid protein of Canine Parvovirus
(W-MSDGAVQPDGGQPAVRNERA) and the non-
immunogenic scrambled peptide (WMSDGAVQPDGGQ-
PAVRNERA) were synthesized via solid phase peptide
synthesis method by Caslo Laboratory ApS (Denmark).
Tryptophan (W) amino acid was also added to the N-
terminus of peptide sequences in order to provide
UV-spectral analysis. PLGA (lactide:glicolide = 50:50; in-
herent viscosity 0.45-0.60 dL/g, Mw~ 38-54 kDa P50/50),
3-(4,5-dimetil triazol-2-il)-2,5-difeniltetrazoliumbromid
(MTT), Fluorescein isothiocyanate (FITC), dimethyl sulf-
oxide (DMSO), and polyvinyl alcohol were purchased
from Sigma Aldrich (St. Louis, USA), dichloromethane
(DCM) was purchased Ridel de Haen. Mouse J774
macrophage cell line was obtained from Histology
and Embryology Department, Istanbul University,
Istanbul, Turkey. Ultra-pure water was obtained from
Millipore MilliQ Gradient system.
Methods
Preparation of polymeric nanoparticles
Canine Parvovirus W-1 L19 peptide was encapsulated as
an antigen in PLGA nanoparticles by a modified water/
oil/water double emulsion solvent evaporation method
[22]. Briefly, primary emulsion between internal aqueous
phase containing peptide (5 mg/ml) and organic phase
(75 mg/ml PLGA in dichloromethane) was prepared by
sonication (55 W, amplitude of % 50, 2 min) (Bandelin
Sonopuls, Germany) over an ice bath. Thereafter, the
resulting primary emulsion (w/o) was added drop wise to
external aqueous phase containing 4 ml PVA (% 2.5 w/v)
and emulsified in an ice-water bath to form the double
emulsion (w/o/w). The emulsifications were carried out
using micro tip probe sonicator set at 55 W of energy
output (Bandelin-sonopuls) for 2 min in an ice bath.
The double emulsion (w/o/w) was diluted in 80 ml
PVA (% 0.5 w/v) solution and the emulsion was stirred
overnight on a magnetic stirrer plate at room temperature
for evaporation of organic phase. The resulting particles
were collected by centrifugation at 10.000 x g for 20 min
(Sartorius-Biofuge), washed three times with ultra-pure
water to remove excess PVA and then lyophilized. We also
prepared FITC loaded nanoparticles, for morphological
investigation with fluorescence microscopy and in vitro
cellular uptake study. Fluorescent nanoparticles were fab-
ricated in a similar method where FITC was used in place
of peptide. An equivalent volume of ultra-pure water was
similarly encapsulated in P50/50 to serve as a control
(Free NP). All lyophilized nanoparticles were stored at
−80 °C until used.
Encapsulation efficiency and peptide loading capacity
Peptide encapsulation efficiency (EE) was detected via
indirect quantification methods by using UV-Vis Spec-
troscopy at 280 nm. EE was determined by measuring
the concentration of free peptide in supernatant which
obtained from the ultracentrifugation of nanoparticles.
The peptide concentration in the supernatant was deter-
mined by comparing the concentration to a previously
constructed standard calibration curve. The concentration
of loading peptide was calculated indirectly by calculating
the differences between the initial concentrations of the
peptide used (5 mg/ml) and the concentration of free
peptide in supernatant.
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The peptide encapsulation efficiency (EE) and the
peptide loading capacity (LC) were calculated using
the formulas given below:
EE ¼ A‐B=Að Þ  100 ð1Þ
LC ¼ A‐B=Cð Þ  100 ð2Þ
Where A is the total peptide amount, B is the free pep-
tide amount, and C is the quantified nanoparticle weight
[19]. A standard calibration curve of the absorbance as a
function of peptide concentration was studied at 280 nm.
All measurements were performed in triplicate.
Atomic force microscopy (AFM), scanning electron
microscopy (SEM), fluorescent microscopy (FM)
Both atomic force microscopy (AFM) and scanning elec-
tron microscopy (SEM) were used to ascertain surface
morphology and size of nanoparticles (free and peptide
loaded). AFM (Shimadzu SPM 9600, Japan) studies were
performed as previously described [23]. About 5 μl each
of nanoparticle solution were dropped to freshly cleaved
1 cm2 mica surface and incubated for 5 min. Mica
surface was rinsed with ultra-pure water and dried
for 20 min, the morphological analysis was performed
by dynamic mode in 2-dimensional (2-D) and 3- di-
mensional (3-D).
SEM was used to verify uniformity of nanoparticle
shape and size as previously described [24]. The fabri-
cated nanoparticles were dropped onto black carbon
tape with a double-side. After that, they were vacuum-
coated with a platinum mixture for 45 s and morpho-
logically analyzed with a FE-SEM (CamScan Apollo 300
Field-Emission SEM, UK) at 20 kV.
Fourier transform infrared (FT-IR) spectrometry
Infrared Spectroscopy of the samples was performed in
IR-Prestige 21 FTIR Spectrophotometer (Shimadzu,
Japan). FT-IR spectra were recorded for P50/50, W1L-19
peptide and peptide loaded nanoparticle in universal
attenuation total reflectance (ATR) mode. The measure-
ment range was 4000–750 cm−1, scan number for per
sample was 16, and resolution was 4 cm−1.
Particle size, zeta potential and polydispersity index (PdI)
The intensity size distribution, the Z-average (Z-Ave),
and PdI of nanoparticles were performed by using dy-
namic light scattering technique using a Zetasizer
(Zetasizer Nano ZS, Malvern, UK) instrument equipped
with 4.0 mV He-Ne laser (633 nm). Measurements were
carried out at 25 ± 0.1 °C with using 0.8872 cP of viscosity
and 1.330 of refractive index for the solutions. The
number of runs and run durations were chose as
automatically. Electrophoretic light scattering (ELS) is
used for zeta potential (ζ) measurement of particles
and carried out in the folded capillary cell at 25 ±
0.1 °C. The measurements were performed with the
following parameters: viscosity, 0.8872 cP; dielectric
constant, 79; f(ka), 1.50 (Smoluchowski). The meas-
urement durations and voltage selections were set to
automatic mode.
All samples were prepared by diluting with phosphate
buffer saline (PBS), filtered with a 0.20 μm RC-
membrane filter (Sartorius) before measurement, and all
measurements were performed three times.
In vitro peptide release
The release of the W-1 L19 peptide in vitro from the
peptide loaded nanoparticle were determined following
the method of Dixit et al. [25]. Briefly the peptide loaded
nanoparticle aliquots suspended in PBS (pH 7.4) with %
0.01 sodium azide and the suspension were incubated at
37 °C in a shaking incubator (60 rpm). At predetermined
time intervals (6 h, 12 h, 1, 3, 7, 14, 21, 28, 35, 42 days),
tubes were centrifuged, and the supernatants were
collected followed by resuspension pellet in fresh PBS.
The peptide concentration in the supernatant was deter-
mined with UV-Vis Spectroscopy at 280 nm by comparing
the concentration to a previously constructed standard
calibration curve.
Morphological changes depend on the time
In order to examine morphological changes depending
on the time (during the degradation of nanoparticles),
the nanoparticle suspension in PBS were incubated at
37° and samples were analyzed in 30 and 60 days
with AFM.
Cell viability assay
Cell viability assays of nanoparticles and peptides were
performed on J774 cell lines by MTT method. Briefly,
3 × 104 cells/ml were seeded into microplates and were
incubated overnight. After incubation, different concen-
trations of nanoparticles and peptides ranging from
1 mg/ml to 0.01 mg/ml in PBS were added onto cells.
Following to 48 h incubation at 37 °C, 10 μl MTT reactant
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide (10 mg/ml) were included into all wells of micro-
plates in order to assess susceptibility of cells against
agents. When formazan crystals that are signature of
viability were detected, these crystals were dissolved
by DMSO. Then colorimetric density in microplates
was read by using a Microplate Reader at 570 nm.
Cellular uptake study
In order to observe uptake of nanoparticles into macro-
phages, 5 × 104 cells/ml were seeded into each wells of a
6 well-plate. Following to one night incubation, nanopar-
ticles at the concentrations of 0.5 mg/ml, which was
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detected as non-toxic concentration for macrophages
were put in each wells of the plate. Cellular uptake was
visualized by a florescence microscope thanks to fluores-
cein molecule which was embedded into nanoparticles.
Photographs related to uptake were taken by Olympus
C-5050 digital camera.
Quantification of nitrix oxide (NO) level
In experiments, in order to evaluate nitric oxide produc-
tion following to nanoparticle and peptide formulations,
we used non-toxic concentration (500 μg/ml) of both
nanoparticles and peptide. In concentrations higher than
500 μg/ml, there was a sharp decline in viability values
of J774 cells in regardless of nanoparticle and peptide.
Therefore, a concentration of 500 μg/ml was chosen
both nanoparticles and peptides. For this experiment,
5 × 104 J774 macrophage cells were seeded into 96 well
microplate. After overnight incubation, macrophage cells
were exposed to free NP, peptide loaded NP and peptide
with the concentrations of 500 μg/ml, while only PBS
was used in control group. Following to 48 h incubation,
supernatants above the cells were picked up and 50 μl of
supernatants from each group were transferred to an-
other microplate. In order to observe colorimetric reac-
tion and evaluate nitric oxide production, 50 μl of griess
reactive was transferred to all wells of new microplate.
On the other side, different concentrations of nitride
were used as control. After 30 min incubation at room
temperature, microplate was read at 540 nm absorbance
by using a Microplate-Reader.
Statistical analysis
All experiments were repeated at least three times in
triplicate wells. Data were expressed as mean ± standard
deviation. All statistical analyses were performed using
SPSS 15.0 [26]. Non parametric analysis with Mann-
Whitney U-test was carried out on the data of the bio-
logical variables to examine differences between the
groups. P value less than 0.05 (p < 0.05) was accepted as
significant.
Results and discussion
Encapsulation efficiency and loading capacity
The w/o/w double emulsion solvent evaporation method
was used for fabrication of W-1 L19 peptide loaded
PLGA nanoparticles. The ratio of aqueous phase (con-
taining W-1 L19 peptide) to organic phase (containing
PLGA) was kept low for production of nano-size parti-
cles as this ratio directed affects the particle size. First,
we determined process yield, peptide loading capacity,
and encapsulation efficiency. Lyophilized nanoparticles
were weighed and yield of the process was estimated to
be 81.2 ± 3.1 %. Peptide loading capacity and encapsula-
tion efficiency were determined by measuring the
concentration of free peptide in supernatant which ob-
tained from the ultracentrifugation of nanoparticles. Our
results from indirect methods employed for calculate the
EE and LC and they were found 85.3 ± 2.2 % and 5.26 ±
0.05 % respectively.
Physicochemical properties of nanoparticles
The nanoparticles have uniform size distribution,
smooth surface and spherical shape is considered the
best for an antigen depot (adjuvant) and to provide a
controlled release formulation [11, 27, 28]. SEM (Fig. 1)
and AFM images (Fig. 2) showed that the fabricated
nanoparticles were typically spherical in shape and
smooth surfaced with no cavities overall in most of ob-
served particles.
Fourier transform infrared (FT-IR) analysis
The FT-IR spectra of peptide, PLGA and peptide loaded
NPs were presented in Fig. 3. PLGA sample showed
peaks such as aliphatic –CH stretching (2850–2950 cm−1),
carbonyl –C =O stretching (1700–1800 cm−1 strong and
narrow), C–O stretching (1050–1250 cm−1). The free
peptide sample showed the main peaks contributed by
the functional groups of molecules such as carboxylic acid
O-H stretching (2500–3000 cm−1, board), overlapped
amine and amide N-H stretching (3300–3500 cm−1 and
3500–3700 cm−1) and amide C =O stretching (1600–
1690 cm−1). However, in the FTIR spectra for peptide
loaded nanoparticles, the major peak of peptide at 1600–
1690 cm−1 was significantly lowered. This indicated that
the peptide was encapsulated in PLGA nanoparticles
successfully.
Particle size, zeta potential and PdI measurements
The size and size distribution of nanoparticles were in-
vestigated by dynamic light scattering technique. Particle
size and surface characteristics, plays an important role
in vitro and in vivo [20], such as determining the level of
cellular and tissue uptake and immun response [27–30].
Also, zeta potential is one of the most important particle
properties affecting particle stability. Figure 4 shown in-
tensity size distribution of free (A) and peptide loaded
(B) nanoparticles, respectively. Table 1 represent Z-Ave,
PdI and Zeta Potential of free and peptide loaded parti-
cles. As it could be observed in Fig. 4 and Table 1 that,
although peptide encapsulation had significant effect on
the particle size, on zeta potential hadn’t significant ef-
fect. In the present study, Z-Ave of peptide loaded nano-
particles was approximetely 221.7 ± 15.8 nm (d. nm),
which is in the good size range for cellular uptake [31].
Similarly, the Z-Ave of free nanoparticles fabricated in
this study was 183.9 ± 12.1 nm (d. nm).
The free and peptide loaded nanoparticles showed a
negative surface charges of around 36.8 ± 3.5 and 35.1 ±
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Fig. 1 Scanning electron microscope image of free (a) and peptide loaded (b) PLGA nanoparticles (Magnification 5000x). Fluorescence
microscope (40×) image of FITC + peptide loaded nanoparticles (c)
Fig. 2 2-Dimensional (a and c) and 3-Dimensional (b and d) atomic force image of free (a and b) and peptide loaded (c and d) PLGA nanoparticles
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2.9 mV, respectively which means that they were stable
in dispersion state (Table 1). Further, PdI values are
0.107 ± 0.08 and 0.135 ± 0.12 for free and peptide loaded
nanoparticle, respectively. The nanoparticles exhibited a
relatively narrow PdI (less than 0.15) indicating the
monodisperse formulation, which is useful for treatment
effect [20].
In vitro release study of peptide loaded nanoparticles
The in vitro controlled release study was evaluated in
PBS at pH 7.4. As shown in Fig. 5, a triphasic release
pattern could be seen at this condition. In the first
7 days, a burst release showed with approximately 45 %
of peptide was released. For the second part of kinetic,
peptide release reached a plateau in the next 14 days,
with a cumulative release of 70.4 %. Additionally, almost
75 % of peptide was cumulatively released form nano-
particles within 42 days and no further release was
observed (Fig. 5). Encapsulation to PLGA provided a
slow release of peptide [32], which is an interesting
attribute property for a vaccine candidate as this may
reduce the immunization number as well as enhan-
cing the presentation of peptide to Antigen presenting
cell (APC) [19].
Morphological changes depend on the time
Also we examined morphological changes of nanoparti-
cles in PBS at pH 7 during the degradation in 30th and
60th days with AFM. Time dependent-morphological
changes during degradation period in 30 days and
60 days were shown in Fig. 6a, b, c and d, respectively.
PLGA nanoparticles show morphological changes after
the 30 day period and significant changes for 60th days.
Especially AFM views related to morphology of nano-
particles at the day 60 demonstrated that nanoparticles
lost their spherical shapes and this can be explained by
the hydrolysis of PLGA nanoparticles. In Fig. 6c and d,
the area outside of nanoparticles within release medium
were observed as “foggy”. This turbidity may be ex-
plained by hydrolysis of nanoparticles and release of
peptide antigen to the medium.
Cell viability assay
According to the results (Fig. 7), concentrations between
100 μg/ml and 500 μg/ml are found as non-toxic on
J774 macrophage cells for free and peptide loaded NP
formulations and peptides. In concentrations higher than
500 μg/ml there were sharp declines in viability values of
macrophages. When the cells were morphologically ana-
lyzed, it was also observed that macrophages that were
exposed to concentrations higher than 500 μg/ml lost
their stabilities and amounts of formazan crystals that
are signs of cellular viability decreased, substantially in
contrast to control group. On the other side, macrophages
Fig. 3 Furier transforms-infrared spectroscopy studies of PLGA
(50/50) polymer, free nanoparticle and peptide loaded nanoparticles
Fig. 4 Size distribution analysis of free (a) and peptide loaded (b) nanoparticles
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that were exposed to formulations at 500 μg/ml, stayed
compact and amounts of formazan crystals within the
cells were close to control. IC50 values of free NP, peptide
loaded NP and peptides were assessed as 750, 740
and 650 μg/ml, respectively. Due to these results,
concentration of 500 μg/ml was selected for further
nitric oxide evaluation and cellular uptake assays,
since this concentration was considered as the highest
nontoxic concentration.
Cellular uptake
When cellular uptake of nanoparticles was observed by
using fluorescence microscope, it was detected that
nanoparticles were easily phagocyted into macrophages
and located in their vacuoles independent from the con-
centrations of nanoparticles. Uptake of fluorescence
loaded nanoparticles into macrophages was demon-
strated in Fig. 8. From the figure it was also seen that
macrophages protect their compact structure and no
cytotoxic effect was available. Interaction between nano-
particles and macrophages shows that nanoparticles can
easily penetrate into phagocytes and can present anti-
gens that they are carrying for activating macrophages
to compose immunogenic responses.
Quantification of nitrix oxide (NO) Level
According to the results, it was observed that a peptide
loaded NP formulation induced nitric oxide production
of macrophage cell much higher than peptide and free
NP use alone. In group that was exposed to peptide
loaded NPs, macrophages produced approximately 3 fold
nitric oxide in contrast to macrophages in control and
experiment group that was exposed to free nanoparticles
that did not contain any antigenic molecules. Similarly,
macrophages exposed to peptide loaded NPs produced
approximately 2 fold nitric oxide in contrast to macro-
phages exposed to only peptide antigen (Fig. 9). Since ni-
tric oxide that are produced by macrophages is one of the
important factors of immune system in regards to fighting
against microorganisms, determination of enhanced nitric
oxide levels in macrophages that are induced by peptide
antigen containing nanoparticles can be a corner step in
activating immune system and developing new vaccine
candidates based on delivery systems.
Conclusion
Poly(DL,lactic-co-glycolic acid) is approved by Food and
Drug Administration (FDA) and widely used copolymer
for nanoparticular delivery system, owing to its bio-
degradability and biocompatibility [12]. In the previous
studies demonstrate that, PLGA nanoparticles have adju-
vant effect for various vaccine antigens [17, 33–35].
However, we could not find any study in literature inves-
tigating immunogenic features of PLGA nanoparticles as
adjuvants against Canine Parvovirus.
In this study, for the first time, W-1 L19 peptide
loaded PLGA nanoparticles were successfully synthe-
sized by using water/oil/water double emulsion solvent
evaporation method. Results of particle characterization
with SEM, AFM, FT-IR and zetasizer demonstrated that
synthesized particles were nano-sized, narrow sized dis-
tributed and smooth spherical shaped. Moreover, con-
trolled release of W-1 L19 peptide from the particles
were observed under physiological pH (7.4). According
to biocompatibility tests of nanoparticles that were
maintained on J774 cell lines, non-toxic concentrations
of W-1 L19 peptide loaded PLGA nanoparticles were
found and their high immunogenic features were de-
termined by evaluation of nitric oxide amounts in
macrophages cells.
As it is known, in vaccine delivery researches based on
PLGA nanoparticles, especially 200-500 nm ranged parti-
cles are preferred [11, 27, 28, 36, 37]. That’s why at these
dimensions, PLGA nanoparticles can easily activate den-
dritic cells, antigen specific T helper cells and cytotoxic T
lymphocyte cells in order to generate high humoral and
cellular immune response, they can be endocytosed by
antigen presenting cells (APCs) as well [11, 14, 37].
In the present study, we encapsulated Canine Parvovirus
W-1 L19 antigenic peptide to PLGA (50:50) nanoparticles
by double emulsion solvent evaporation method [22] with
small modifications. PLGA nanoparticles were produced
with 5.26 ± 0.05 % loading capacity and high encapsulation
Table 1 Size distribution, zeta potential and PdI values of
nanoparticles
Nanoparticles Z-Ave (d.nm) PdI Zeta potential (mV)
Free nanoparticle 183.9 ± 12.1 0.107 ± 0.08 −36.8 ± 3.5
Peptide loaded
nanoparticle
221.7 ± 15.8 0.135 ± 0.12 −35.1 ± 2.9
Fig. 5 In vitro cumulative release of W1L-19 peptide from encapsulated
PLGA nanoparticles in PBS incubated at 37 °C
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efficiency with 81.2 ± 3.1. Additionally, it was evaluated
that free NPs and W-1 L19 peptide encapsulated PLGA
nanoparticles have Z-ave of 183.9 ± 12.1 nm and 221.7 ±
15.8 nm, respectively. It can be thought that synthesized
nanoparticles are small enough to interact with APCs and
induce cellular and humoral immune response.
Zeta potential is the essential particle characteristic and
affecting particle stability, all of studies about zeta poten-
tial of PLGA nanoparticle resulted that PLGA nanoparti-
cles which were prepared with PVA as a surfactant has a
negative surface charge [14, 19, 20, 31, 38, 39]. Similarly in
our study, the zeta potential of free NPs and peptide
Fig. 6 2-Dimensional (a and c) and deflection (b and d) AFM image of nanoparticles after 30 days (a and b) and 60 days (c and d) incubation in
PBS at pH 7.4
Fig. 7 Cytotoxicity of nanoparticles and peptide on J774 macrophage cells
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loaded NPs was −36.8 ± 3.5 mV and −35.1 ± 2.9 mV
respectively, indicating a high stability due to the high
repulsion between nanoparticles.
Characterization of W-1 L19 peptide encapsulated
PLGA nanoparticles with AFM and SEM exhibited that
synthesized nanoparticles were smooth surfaced and
spherical in shape. In several studies, uses of smooth
and spherical nanoparticles were suggested as well adju-
vant activity for antigens and there was no requirement
to apply booster doses of vaccines since they provide op-
portunity to controlled release by degradation of PLGA
nanoparticles [11, 27, 36]. In general biodegradation of
nanoparticulate vaccine delivery systems are investigated
by evaluating release kinetics. For the first time, in this
study, we visualized nanoparticulate system for 30 and
60 days in physiological conditions (pH 7.4 and 37 C) by
using AFM. According to AFM images, we determined
that nanoparticles protected their spherical shapes at the
end of 30th days, while nanoparticles were totally lost
their compact structures at the end of 60th days showing
that PLGA nanoparticles released high amounts of
W-1 L19 antigens to the medium.
In studies targeting development of vaccine delivery
systems, long-time release of antigens from nanoparti-
cles is crucial as they can provide long-term-protection
against diseases [11, 14, 40]. This may also reduce quan-
tities of immunization process and increase the antigen
presentations to APCs [40]. Depending on their bio-
degradable features which lead to long-term controlled
release as well as biocompatibility, PLGA nanoparticles
have been widely studied in vaccine development espe-
cially against infectious diseases [11, 18, 25] and cancer
[21, 41–43]. Taha et al exhibited that PLGA nanoparti-
cles caused the 20 % release of Major Outer Membrane
Protein (MOMP) at one day and 48.6, 70 and 100 % of
antigen were released at first, second and third week, re-
spectively [19]. Manish et al studied on protective effica-
cies of Immunogenic Domain 4 of Protective Antigen
(PAD4) loaded PLGA nanoparticles against Bacillus
anthracis. This group demonstrated that 50 % of PAD4
antigens released from nanoparticles during first 24 h.
Totally 75 % of PAD4 antigens released at the end of
4 weeks [11]. In the another study, Primard et al, pre-
pared multifunctional PLGA nanoparticles by encapsu-
lating an immunomodulator Imiquimod (IMQ) and BSA
as an antigen in order to target Toll-like Receptor 7. In
these study, it was shown that PLGA nanoparticles rap-
idly released % 40 of IMQ at 24 h [39]. As it is clearly
seen, in most of studies, PLGA nanoparticles showed
high burst-release kinetics which is identified as high
amounts of antigens’ release in 24 h [11, 19, 39]. However,
in some studies it was pointed out that high burst release
especially in 24 h is not preferred since it leads to low T
cell response and antigen encapsulated nanoparticles with
Fig. 8 Fluorescence microscope images with 10 × (a) and 40 × (b) magnification of J774 macrophages exposed to FITC + peptide loaded
nanoparticles for 24 h at 37 °C under 5 % CO2 in complete media
Fig. 9 Nitric oxide production of J774 macrophage stimulated with
free NP, peptide loaded NP and peptide. Significant differences in
production of nitric oxide from stimulation are marked with asterisks.
Significance levels of *P < 0.05, **P < 0.01, by non-parametric
Mann-Whitney U-test
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low burst release features may demonstrate better vaccine
activity. For that reason, Silva and colleagues synthesized
24-residue long synthetic antigenic peptide of Ovalbumin
(OVA24) peptide encapsulated PLGA nanoparticles with
w/o/w double emulsion method and studied on diminish-
ing burst release of antigens from nanoparticles by chan-
ging first and second emulsion medium. These group
compared low (<10 %) and high (75 %) burst release in
terms of immunogenic properties and found out that low
burst release resulted in higher T cell response [14]. Simi-
larly, in our study, only 7 % of antigens were released at
first 24 h which indicates sustained slow release. Our re-
sults overlapped with similar studies [14, 44–46] since
antigen release from PLGA nanoparticles were shown
to be biphasic release character. These results show
that our synthetized particles might be attractive can-
didate for further vaccine studies.
One of the most important properties of PLGA nano-
particles is improving biocompatibility and bioavailability
of biologically active molecules such as peptides, drugs,
proteins etc [47]. In several studies, it has been shown
that encapsulation of antigenic molecules into PLGA
nanoparticles decreased their toxicity as well as enhan-
cing their bioavailability [11, 14, 17–21, 25, 38, 39, 48].
Our findings demonstrated that IC50 values of free NP,
peptide loaded NP and peptides were assessed as 750,
740 and 650 μg/ml, respectively. In all of studied con-
centrations, encapsulation of peptides into PLGA nano-
particles increased applied dosages of peptides since
viability amounts of macrophages that were exposed to
free peptides were lower than macrophages that were
exposed to peptide loaded PLGA nanoparticles [11, 14,
17–19, 21, 39, 48]. This is related to special features of
PLGA nanoparticles that enhance biocompatibility of
used antigens. For nitric oxide production and cellular
uptake studies, concentrations of 500 μg/ml were chosen
as macrophage cells stayed compact and showed no
cytotoxicity on J774 macrophage cells, while at concen-
trations higher than 500 μg/ml macrophage cells started
to lose their compact morphology and their viability
values decreased sharply.
As it is known, phagocytosis of a particle into macro-
phage cells is influenced by the size, shape and surface
properties. In various studies, it was demonstrated that
PLGA micro/nanoparticles were internalized by macro-
phages with different pathways such as phagocytosis
(particle size: 0.5 μm-10 μm) macro-pinocytosis (particle
size: 100 nm-5 μm), clathrin-mediated pinocytosis
(particle size: approximately 120 nm), caveolin-mediated
pinocytosis (particle size: approximately 80 nm), clathrin-
and caveolin-independent pinocytosis (particle size:
approximately 50 nm) [49–51]. However, accurate uptake
mechanisms of PLGA nanoparticles have not been under-
stood clearly, anymore. According to literature data,
we can think that our nanoparticles which was sized
as 221.7 ± 15.8 nm, may internalize into macrophages
by using macro-pinocytosis pathway [52].
Nitric Oxide (NO) is one of the most important im-
mune-effector molecules in the body, playing role in
host defense in bacteria, fungi, parasites and viruses [53,
54]. NO can enhance immune response again infections
by stimulating cytokine production and leading macro-
phages to kill intracellular pathogens [55]. Therefore, in
vaccine studies, determination of increased NO levels fol-
lowing to exposure to applied immunogenic molecule is
substantial since it is the sign of augmented immune re-
sponse. Accordingly, in our study, we studied on produc-
tion of NO by macrophages after treatment with control
(PBS), free PLGA nanoparticles, peptide alone and peptide
loaded PLGA nanoparticles. Due to the results, it was de-
termined that peptide loaded PLGA nanoparticles in-
creased NO production at 2-folds ( P < 0.05) in contrast
to free peptide, and 3-folds ( P < 0.01) in contrast to
control and free PLGA nanoparticles. The significant dif-
ference especially between peptide loaded nanoparticles
and free nanoparticles can be explained by high adjuvant
features of PLGA nanoparticles [27]. We think that PLGA
nanoparticles enhanced antigenicity of peptides due to
their special properties while it did not stimulate any im-
mune response as a good adjuvant need to do. This impli-
cated that peptide loaded PLGA nanoparticles were good
at enhancing immune response and may also stimulate
the other immunological pathways.
In conclusion, to our knowledge this is the first study
to synthesis and characterization and in vitro evaluation
of W-1 L19 peptide encapsulated PLGA50:50 nanoparti-
cles and its immunostimulating effect on J774 Murine
macrophage-like cells. Both particles size distribution,
zeta potential and sustained slow release of antigenic
peptide from nanoparticles together with accomplish-
ments to induce significantly higher NO production
than free peptide, propose that nanoparticular system
can be interesting vaccine candidate against Canine
parvovirus infections. However, we think that much
more efforts must be performed especially on the subject
of in vitro stimulation of immune response following to
W-1 L19 peptide encapsulated PLGA50:50 nanoparticles
exposure. Moreover, obtained data is promising to test
the immunogenicity and efficacy of W-1 L19 as a nano-
vaccine candidate against Canine Parvovirus in mice.
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